Oppenheimer analyst Leland Gershell assumed coverage of Acceleron Pharma and upgraded the shares to Outperform from Perform with a $59 price target. The company is "on the cusp" of generating revenue from product sales as well as entering a period of key pipeline newsflow, Gershell tells investors in a research note. Further, the analyst expects U.S. and European approval next year of luspatercept for anemia in two "significant" unmet medical needs, myelodysplastic syndromes and N2-thalassemia. Gershell views Acceleron's $2B peak sales guidance for the drug as conservative.